A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression — Stella
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
Banner Health, Gilbert, Arizona
UCSD Moores Cancer Center, La Jolla, California
UCLA Medical Center, Los Angeles, California
Stanford University, Stanford, California
Mayo Clinic, Jacksonville, Florida
Moffitt Cancer Center, Tampa, Florida
Mayo Clinic Rochester, Rochester, Minnesota
Washington University, St Louis, Missouri
NYU Langone Medical Center, New York, New York
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Vanderbilt University Medical Center, Nashville, Tennessee
Fred Hutchinson Cancer Center, Seattle, Washington